4//SEC Filing
Johnson Anne Nagengast 4
Accession 0000950170-24-112935
CIK 0001840904other
Filed
Oct 3, 8:00 PM ET
Accepted
Oct 4, 4:30 PM ET
Size
11.9 KB
Accession
0000950170-24-112935
Insider Transaction Report
Form 4
Johnson Anne Nagengast
Chief Financial Officer
Transactions
- Disposition to Issuer
Stock Option
2024-10-04−326,416→ 0 totalExercise: $5.68Exp: 2025-08-20→ Common Shares (326,416 underlying) - Award
Stock Option
2024-10-04+326,416→ 326,416 totalExercise: $5.68Exp: 2030-08-20→ Common Shares (326,416 underlying) - Award
Stock Option
2024-10-04+115,152→ 115,152 totalExercise: $11.71Exp: 2030-08-20→ Common Shares (115,152 underlying) - Disposition to Issuer
Stock Option
2024-10-04−115,152→ 0 totalExercise: $11.71Exp: 2025-08-20→ Common Shares (115,152 underlying)
Footnotes (3)
- [F1]No new stock options have been awarded. The transactions reported herein reflect the extension of the expiration date of certain pre-IPO stock options to align them with options granted under the Issuer's 2021 Incentive Award Plan, which is consistent with prevailing market practices.
- [F2]The stock option is fully vested and currently exercisable.
- [F3]The stock option vested as to 25% of the underlying shares on April 29, 2022, and the remaining underlying shares vest in 36 substantially equal monthly installments thereafter.
Documents
Issuer
ATAI Life Sciences N.V.
CIK 0001840904
Entity typeother
Related Parties
1- filerCIK 0001976640
Filing Metadata
- Form type
- 4
- Filed
- Oct 3, 8:00 PM ET
- Accepted
- Oct 4, 4:30 PM ET
- Size
- 11.9 KB